We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

62 hedge funds and large institutions have $302M invested in Intellia Therapeutics in 2016 Q2 according to their latest regulatory filings, with 62 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
62
Holders Change
+62
Holders Change %
–
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
62
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$140M
2
O
OrbiMed
New York
+$70.8M
3
BBA
Baker Bros. Advisors
New York
+$28.3M
4
Temasek Holdings
Temasek Holdings
Singapore
+$21M
5
FCMI
Foresite Capital Management III
California
+$20.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$112M +$140M +5,254,407 New
O
2
OrbiMed
New York
$56.8M +$70.8M +2,662,180 New
BBA
3
Baker Bros. Advisors
New York
$22.7M +$28.3M +1,062,120 New
Temasek Holdings
4
Temasek Holdings
Singapore
$16.9M +$21M +790,527 New
FCMI
5
Foresite Capital Management III
California
$16.3M +$20.3M +763,688 New
BA
6
BlackRock Advisors
Delaware
$13.1M +$16.4M +615,749 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.89M +$11.1M +416,564 New
EC
8
EcoR1 Capital
California
$6.63M +$8.27M +310,695 New
Morgan Stanley
9
Morgan Stanley
New York
$6.43M +$8.02M +301,358 New
Franklin Resources
10
Franklin Resources
California
$6.41M +$7.98M +300,000 New
AG
11
Artal Group
Luxembourg
$4.8M +$5.99M +225,000 New
BFA
12
BlackRock Fund Advisors
California
$3.5M +$4.36M +163,768 New
Goldman Sachs
13
Goldman Sachs
New York
$3.07M +$3.83M +144,002 New
TCM
14
Tekla Capital Management
Massachusetts
$1.85M +$2.31M +86,842 New
Invesco
15
Invesco
Georgia
$1.77M +$2.21M +82,994 New
Neuberger Berman Group
16
Neuberger Berman Group
New York
$1.65M +$2.06M +77,486 New
Northern Trust
17
Northern Trust
Illinois
$1.61M +$2.01M +75,683 New
State Street
18
State Street
Massachusetts
$1.51M +$1.89M +70,874 New
SAM
19
Sectoral Asset Management
Quebec, Canada
$1.47M +$3.28M +123,159 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$1.44M +$1.79M +67,346 New
EA
21
Emerald Acquisition
Washington
$1.3M +$1.62M +60,954 New
JP Morgan Chase
22
JP Morgan Chase
New York
$1.3M +$1.62M +60,925 New
BIT
23
BlackRock Institutional Trust
California
$1.24M +$1.54M +57,913 New
GL
24
GLG LLC
New York
$730K +$909K +34,176 New
LCM
25
Landscape Capital Management
New Jersey
$582K +$725K +27,268 New
1
2 3

NTLA Hedge Fund Activity: Q2 2016 in Review

62 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2016, worth a combined $302M.

Buyers outnumbered sellers: 62 funds opened new NTLA positions and 0 closed out — a net gain of 62 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $140M.

  • 62 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2016, up from 0 in Q1 2016.
  • Funds reported $302M of Intellia Therapeutics stock for Q2 2016.
  • 62 funds opened new Intellia Therapeutics positions in Q2 2016 and 0 closed out, a net change of +62 holders.
  • The largest Intellia Therapeutics buyer in Q2 2016 was Fidelity Investments, an estimated $140M added.

Based on aggregated 13F filings for Q2 2016.